Precursor B-cell acute lymphoblastic leukemia
MONDO:0020511The most frequent type of acute lymphoblastic leukemia. Approximately 75% of cases occur in children under six years of age. This is a good prognosis leukemia. In the pediatric age group the complete remission rate is approximately 95% and the disease free survival rate is 70%. Approximately 80% of children appear to be cured. In the adult age group the complete remission rate is 60-85%. (WHO, 2001)
Also known as: B acute lymphoblastic leukaemia, B acute lymphoblastic leukemia, B cell acute lymphocytic leukaemia, B cell acute lymphocytic leukemia, B-ALL, B-cell acute lymphoblastic leukaemia, B-cell acute lymphoblastic leukemia, B-cell acute lymphocytic leukaemia
2114 clinical trials for this condition and its sub-types, 66 tagged with Precursor B-cell acute lymphoblastic leukemia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Precursor B-cell acute lymphoblastic leukemia
-
B-cell adult acute lymphocytic leukemia 12 trials
-
New immune cell therapy targets Hard-to-Treat leukemia in early trial
Disease control Stopped earlyThis early-phase trial tests a new treatment called CD19 t-hANK for people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back after previous treatments. The therapy uses specially designed immune cells to attack cancer cells. Up to 10 participant…
Phase 1 • Sponsor: ImmunityBio, Inc. • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Leukemia drug spectrila tested in adults: phase 2 trial looks at drug levels and safety
Disease control Stopped earlyThis study tested the drug Spectrila (a form of L-asparaginase) in 40 adults aged 18-55 with newly diagnosed B-cell acute lymphoblastic leukemia. The goal was to see if the drug reached effective levels in the blood and to check its safety and immune response. The trial was termi…
Phase 2 • Sponsor: medac GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Promising leukemia drug falls short in kids trial
Disease control Stopped earlyThis phase 2 trial tested inotuzumab ozogamicin (Besponsa) in children with B-cell acute lymphoblastic leukemia who had low levels of remaining cancer cells (MRD) despite treatment. The drug targets CD22, a protein on leukemia cells, and delivers a potent toxin. Only 5 children w…
Phase 2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC